Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | GBA1 | P04062 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391323 | 0.96 | HTR1A (0.56) | HTR1ADRD2HTR2AHTR7GBA1 | |
| SCHEMBL6889648 | 0.88 | HTR1A (0.50) | HTR1ADRD2HTR2AHTR7GBA1 | |
| SCHEMBL15907944 | 0.85 | HTR1A (0.48) | HTR1ADRD2HTR2AHTR7GBA1 | |
| SCHEMBL10396554 | 0.77 | HTR1A (0.48) | HTR1ADRD2HTR2AHTR7GBA1 | |
| SCHEMBL20250954 | 0.77 | HTR1A (0.48) | HTR1ADRD2HTR2AHTR7GBA1 | |
| SCHEMBL1704306 | 0.77 | — | — | |
| SCHEMBL10396090 | 0.77 | HTR1A (0.48) | HTR1ADRD2HTR2AHTR7GBA1 | |
| SCHEMBL8991382 | 0.75 | HTR1A (0.40) | HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL7206025 | 0.74 | — | — | |
| SCHEMBL2351897 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899317-A2 | ENANTIOMERS OF N,N-DIMETHYL-3-(2-THIENYL)-3-HYDROXYPROPANAMINE BORANE AS INTERMEDIATES IN THE SYNTHESIS OF DULOXETINE | Teva Pharmaceutical Industries Ltd (IL) | 2008-03-19 | — | — | EP | claimed |
| US-20080015362-A1 | Process for the preparation of optically active (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine | TEVA PHARMACEUTICALS USA, INC. | 2008-01-17 | — | — | US | claimed |
| WO-2007123900-A2 | ENANTIOMERS OF N,N-DIMETHYL-3-(2-THIENYL)-3-HYDROXYPROPANAMINE BORANE AS INTERMEDIATES IN THE SYNTHESIS OF DULOXETINE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-11-01 | — | — | WO | claimed |
| WO-2023228980-A1 | PRODUCTION METHOD FOR FLUOROPOLYETHER GROUP–CONTAINING COMPOUND | ダイキン工業株式会社 | 2023-11-30 | — | — | WO | disclosed |
| US-11723900-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230226525-A1 | PLATINUM-TUNGSTEN SOLID SOLUTION PARTICLES AND CATALYST CONTAINING SAME | NIPPON SODA CO., LTD. (JP) | 2023-07-20 | — | — | US | disclosed |
| EP-4169611-A1 | PLATINUM-TUNGSTEN SOLID SOLUTION PARTICLES AND CATALYST CONTAINING SAME | Nippon Soda Co., Ltd. (JP) | 2023-04-26 | — | — | EP | disclosed |
| US-20220087995-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-03-24 | — | — | US | disclosed |
| US-10946007-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200316048-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-10-08 | — | — | US | disclosed |
| US-10722504-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-07-28 | — | — | US | disclosed |
| US-20090318720-A1 | Process for selectively synthesising 3 alpha-hydroxychlormadinone acetate | GRUNENTHAL GMBH (DE) | 2009-12-24 | — | — | US | disclosed |
| EP-2114862-A1 | PROCESS FOR THE PREPARATION OF O-DESMETHYL VENLAFAXINE | Merck Generics (UK) Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008093142-A1 | PROCESS FOR THE PREPARATION OF O-DESMETHYL VENLAFAXINE | GENERICS [UK] LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| EP-1899317-A2 | ENANTIOMERS OF N,N-DIMETHYL-3-(2-THIENYL)-3-HYDROXYPROPANAMINE BORANE AS INTERMEDIATES IN THE SYNTHESIS OF DULOXETINE | Teva Pharmaceutical Industries Ltd (IL) | 2008-03-19 | — | — | EP | disclosed |
| US-20080015362-A1 | Process for the preparation of optically active (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine | TEVA PHARMACEUTICALS USA, INC. | 2008-01-17 | — | — | US | disclosed |
| WO-2007123900-A2 | ENANTIOMERS OF N,N-DIMETHYL-3-(2-THIENYL)-3-HYDROXYPROPANAMINE BORANE AS INTERMEDIATES IN THE SYNTHESIS OF DULOXETINE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-11-01 | — | — | WO | disclosed |
| US-20060241298-A1 | Methods for synthesis of dicarbamate compounds and intermediates in the formation thereof | MEDPOINTE HEALTHCARE INC. | 2006-10-26 | — | — | US | disclosed |
| EP-1582250-A2 | Absorbent with improved ocidation resistance and process for deacidifying fluid fluxes | BASF AKTIENGESELLSCHAFT (DE) | 2005-10-05 | — | — | EP | disclosed |
| US-20050202967-A1 | an aliphatic amine, in particular an alkanolamine, and a non-hydroquinoid antioxidant for removal of CO2, H2S, SO2, CS2, HCN, COS, disulfides or mercaptans as impurities in reaction gases formed in the oxidation of organic materials to prevent the emission of above gases | BASF AKTIENGESELLSCHAFT (DE) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015362-A1 | Process for the preparation of optically active (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine | HTR3A, PNMT, TPH1 | HTR1A 4/4885DRD2 78/4885HTR2A 32/4885 |
| US-10946007-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | SLC6A2, SLC6A4, HTR6 | HTR1A 9/4885DRD2 15/4885HTR2A 31/4885 |
| US-20200316048-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | HTR1A 9/4885DRD2 15/4885HTR2A 31/4885 |
| US-11723900-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | SLC6A2, SLC6A4, HTR6 | HTR1A 9/4885DRD2 15/4885HTR2A 31/4885 |
| US-10722504-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | SLC6A2, SLC6A4, HTR6 | HTR1A 9/4885DRD2 15/4885HTR2A 31/4885 |
| US-20220087995-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | HTR1A 9/4885DRD2 15/4885HTR2A 31/4885 |
| US-20060241298-A1 | Methods for synthesis of dicarbamate compounds and intermediates in the formation thereof | CPS1, ME1, TALDO1 | HTR1A 4849/4885DRD2 4226/4885HTR2A 4875/4885 |
| US-20090318720-A1 | Process for selectively synthesising 3 alpha-hydroxychlormadinone acetate | CYP51A1, HSD17B7, HSD17B13 | HTR1A 1914/4885DRD2 1333/4885HTR2A 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.